AR066168A1 - Formulaciones galenicas de compuestos organicos - Google Patents
Formulaciones galenicas de compuestos organicosInfo
- Publication number
- AR066168A1 AR066168A1 ARP080104137A ARP080104137A AR066168A1 AR 066168 A1 AR066168 A1 AR 066168A1 AR P080104137 A ARP080104137 A AR P080104137A AR P080104137 A ARP080104137 A AR P080104137A AR 066168 A1 AR066168 A1 AR 066168A1
- Authority
- AR
- Argentina
- Prior art keywords
- percent
- minutes
- oral dose
- pharmaceutical combination
- dose pharmaceutical
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 150000002894 organic compounds Chemical class 0.000 title 1
- 206010020772 Hypertension Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 abstract 1
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 abstract 1
- 208000021642 Muscular disease Diseases 0.000 abstract 1
- 201000009623 Myopathy Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 abstract 1
- 229960004699 valsartan Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97590907P | 2007-09-28 | 2007-09-28 | |
| US97591907P | 2007-09-28 | 2007-09-28 | |
| US97590107P | 2007-09-28 | 2007-09-28 | |
| US97592507P | 2007-09-28 | 2007-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066168A1 true AR066168A1 (es) | 2009-07-29 |
Family
ID=40377183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104137A AR066168A1 (es) | 2007-09-28 | 2008-09-24 | Formulaciones galenicas de compuestos organicos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100209480A1 (enExample) |
| EP (1) | EP2205233A2 (enExample) |
| JP (1) | JP2010540547A (enExample) |
| KR (1) | KR20100063090A (enExample) |
| CN (1) | CN101808631A (enExample) |
| AR (1) | AR066168A1 (enExample) |
| AU (1) | AU2008309058B2 (enExample) |
| BR (1) | BRPI0817442A2 (enExample) |
| CA (1) | CA2698330A1 (enExample) |
| CL (1) | CL2008002829A1 (enExample) |
| CO (1) | CO6270217A2 (enExample) |
| EC (1) | ECSP10010052A (enExample) |
| MA (1) | MA31706B1 (enExample) |
| MX (1) | MX2010003441A (enExample) |
| PE (1) | PE20090654A1 (enExample) |
| TN (1) | TN2010000135A1 (enExample) |
| TW (1) | TW200924737A (enExample) |
| WO (1) | WO2009045795A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091203A1 (es) * | 2007-09-28 | 2009-09-11 | Novartis Ag | Composiciones farmaceuticas que comprende alisquireno o una sal farmaceuticamente aceptable del mismo |
| AR073651A1 (es) * | 2008-09-24 | 2010-11-24 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| MX2011009844A (es) * | 2009-03-20 | 2011-09-29 | Novartis Ag | Composicion farmaceutica que comprende alisquireno. |
| CN102348452A (zh) * | 2009-03-20 | 2012-02-08 | 诺瓦提斯公司 | 缬沙坦和阿利吉仑的固定剂量组合的盖仑制剂 |
| AR080683A1 (es) * | 2010-03-16 | 2012-05-02 | Novartis Ag | Composiciones farmaceuticas de aliskiren y metodos de administracion |
| TR201002256A1 (tr) * | 2010-03-24 | 2011-10-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Stabil aliskiren formülasyonları |
| CN101926793B (zh) * | 2010-08-05 | 2012-08-15 | 成都自豪药业有限公司 | 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法 |
| EP2766423A1 (en) * | 2011-10-12 | 2014-08-20 | Dow Global Technologies LLC | Injection-molded dosage form |
| WO2013098268A2 (en) * | 2011-12-26 | 2013-07-04 | Novartis Ag | Tablets and dry-coated agents |
| CN103349652B (zh) * | 2013-05-11 | 2014-11-19 | 辽宁大学 | 含有四氢萘酰胺化合物或其可药用盐的高药物载荷片剂 |
| CN116887866A (zh) | 2020-12-03 | 2023-10-13 | 巴特尔纪念研究院 | 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法 |
| JP2024516108A (ja) | 2021-04-07 | 2024-04-12 | バテル・メモリアル・インスティテュート | 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術 |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| US12441996B2 (en) | 2023-12-08 | 2025-10-14 | Battelle Memorial Institute | Use of DNA origami nanostructures for molecular information based data storage systems |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK469989D0 (da) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
| GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| AR048431A1 (es) * | 2004-03-17 | 2006-04-26 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| EP2248520A3 (en) * | 2004-10-08 | 2010-11-17 | Novartis AG | Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure |
| MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
| KR20080000624A (ko) * | 2005-04-27 | 2008-01-02 | 노파르티스 아게 | 아테롬성동맥경화증의 치료 방법 |
-
2008
- 2008-09-24 WO PCT/US2008/077416 patent/WO2009045795A2/en not_active Ceased
- 2008-09-24 CA CA2698330A patent/CA2698330A1/en not_active Abandoned
- 2008-09-24 JP JP2010527091A patent/JP2010540547A/ja not_active Withdrawn
- 2008-09-24 PE PE2008001660A patent/PE20090654A1/es not_active Application Discontinuation
- 2008-09-24 BR BRPI0817442-3A patent/BRPI0817442A2/pt not_active IP Right Cessation
- 2008-09-24 MX MX2010003441A patent/MX2010003441A/es not_active Application Discontinuation
- 2008-09-24 AU AU2008309058A patent/AU2008309058B2/en not_active Ceased
- 2008-09-24 CN CN200880108860A patent/CN101808631A/zh active Pending
- 2008-09-24 EP EP08835022A patent/EP2205233A2/en not_active Withdrawn
- 2008-09-24 KR KR1020107006603A patent/KR20100063090A/ko not_active Withdrawn
- 2008-09-24 US US12/678,877 patent/US20100209480A1/en not_active Abandoned
- 2008-09-24 TW TW097136690A patent/TW200924737A/zh unknown
- 2008-09-24 AR ARP080104137A patent/AR066168A1/es not_active Application Discontinuation
- 2008-09-24 CL CL2008002829A patent/CL2008002829A1/es unknown
-
2010
- 2010-03-17 MA MA32701A patent/MA31706B1/fr unknown
- 2010-03-26 TN TNP2010000135A patent/TN2010000135A1/fr unknown
- 2010-03-26 EC EC2010010052A patent/ECSP10010052A/es unknown
- 2010-04-19 CO CO10045487A patent/CO6270217A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2205233A2 (en) | 2010-07-14 |
| CL2008002829A1 (es) | 2009-06-26 |
| BRPI0817442A2 (pt) | 2015-06-16 |
| MX2010003441A (es) | 2010-04-21 |
| CO6270217A2 (es) | 2011-04-20 |
| AU2008309058A1 (en) | 2009-04-09 |
| WO2009045795A3 (en) | 2009-07-16 |
| TN2010000135A1 (en) | 2011-09-26 |
| WO2009045795A2 (en) | 2009-04-09 |
| TW200924737A (en) | 2009-06-16 |
| AU2008309058B2 (en) | 2012-08-09 |
| KR20100063090A (ko) | 2010-06-10 |
| MA31706B1 (fr) | 2010-09-01 |
| JP2010540547A (ja) | 2010-12-24 |
| PE20090654A1 (es) | 2009-06-27 |
| CN101808631A (zh) | 2010-08-18 |
| US20100209480A1 (en) | 2010-08-19 |
| ECSP10010052A (es) | 2010-04-30 |
| CA2698330A1 (en) | 2009-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075179A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno | |
| ES2651287T3 (es) | Procedimiento para la estimulación de la angiogénesis, la vascularización o la reparación vascular o para la inhibición de la angiogénesis tumoral | |
| CO6270217A2 (es) | Formulaciones galenicas de alisquireno y valsartan | |
| CL2011001848A1 (es) | Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras. | |
| GT201200164A (es) | "nuevos compuestos de espiropiperidina" | |
| MX2021005326A (es) | Compuestos de pirimidinodiona contra estados cardiacos. | |
| AR124688A2 (es) | Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo | |
| ECSP12012048A (es) | Antagonistas del receptor mineralcorticoide no esteroidal | |
| CR11749A (es) | Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina | |
| ECSP12011799A (es) | Compuestos de espiropiperidina y uso farmacéutico de los mismos | |
| CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
| EA201100358A1 (ru) | Дабигатран для чрескожной хирургической катетеризации сердца | |
| MX368157B (es) | Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico. | |
| ECSP11011029A (es) | Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional. | |
| RU2010116526A (ru) | Фармацевтическая комбинация алискирена и валсартана | |
| AR073384A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno y amlodipina, y metodo de preparacion | |
| EA201171125A1 (ru) | Антагонист минералокортикоидного рецептора и способы его применения | |
| AR073651A1 (es) | Formulaciones galenicas de compuestos organicos | |
| AR068539A1 (es) | Formulaciones galenicas de compuestos organicos | |
| PE20061195A1 (es) | Derivado de bencimidazol como antagonista de angiotensina ii | |
| EA201200037A1 (ru) | Терапевтические комбинации никотиновой кислоты и мелдония | |
| CR20110674A (es) | Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del ST | |
| JP2011527984A5 (enExample) | ||
| JP2016505628A5 (enExample) | ||
| PY0639426A (es) | Asociación de un inhibidor de la corriente sinusal if, la ivabradina, y de un inhibidor de la enzima de conversión de la angiotensina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |